Pivoting careers and transitions

21 May 2026 - Utrecht

Speakers

Amber Wezenaar | Postdoctoraal onderzoeker | Prinses Maxima Centre

Amber Wezenaar is a researcher and entrepreneur specializing in immunotherapy. Her work focuses on leveraging advanced imaging technologies to understand and optimize immunotherapies for solid tumors, with the goal of developing more effective cancer treatments.

She is currently in the early stages of fouding a start-up dedicated to next-generation engineered T cell therapies. Her venture won the 2024 Fall Venture Challenge, and she was awarded an NWO Faculty of Impact fellowship in recognition of her ability to translate scientific innovation into entrepreneurial initiatives.

Ruben Postel | Chief Scientific Officer and Founder of Sapreme | Sapreme Technologies

Ruben is the Chief Scientific Officer and Founder of Sapreme. At Sapreme, he steers the scientific developments and innovation of the company to enable the challenge of endosomal entrapment of payloads, paving the way for next-generation therapeutic development. Ruben earned his Ph.D. in Developmental Biology and Genetics from the Hubrecht Institute and worked as a postdoctoral fellow at The Netherlands Cancer Institute (NKI) in the department of Cell Biology. Before founding Sapreme Technologies, he gained experience in the ecosystem of biotech startups working on the development of tumor angiogenesis inhibitors.

About Sapreme Technologies
Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement.The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

FULL PROGRAMME HERE